What is Seres Therapeutics, Inc.'s earnings per share (EPS)?

Seres Therapeutics, Inc. (MCRB) reported diluted earnings per share of $0.64 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Seres Therapeutics, Inc. (MCRB) Financials

MCRB

FY2025 annual

Revenue $789K YoY not available

Net Income $5.7M +4088.2% YoY

EPS (Diluted) $0.64 YoY not available

Free Cash Flow $865K +100.6% YoY

Market Cap $27.2M as of Oct 10, 2026

Price / Sales 34.5x on $789K revenue, FY2025

Price / Earnings 4.8x on $5.7M net income, FY2025

Price / Book 0.8x on $34.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MCRB SEC filings page.

Seres Therapeutics, Inc. (MCRB) reported $789K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MCRB FY2025 2026-10-03

Seres remains a development-stage business: research spending overwhelms revenue, while reported FY2025 profit does not come from operations.

FY2025 paired a $94.0M operating loss with $5.7M of net income, so the accounting profit was not produced by the core operating business. Operating cash flow of $1.1M and free cash flow of $865K were also positive, but alongside the operating loss they point to non-operating or non-recurring drivers rather than a self-funded operating model.

Research and development consumed $49.1M against only $789K of FY2025 revenue, a development-stage cost structure in which investment remains vastly larger than the reported commercial base. The operating loss therefore reflects continued spending ahead of meaningful revenue scale, not weak efficiency at a mature sales volume.

Equity rose from $13.8M in FY2024 to $44.2M in FY2025, indicating a materially reshaped funding position rather than an improvement driven by operations. The current ratio of 2.6x provides more short-term asset coverage, while debt-to-equity of 2.1x still shows liabilities are substantial relative to the equity base.

Financial Health Signals

Financial health score not available

Seres Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-11.65

Seres Therapeutics, Inc. scores -11.65, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($27.2M) relative to total liabilities ($94.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/7

Seres Therapeutics, Inc. passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.20x

For every $1 of reported earnings, Seres Therapeutics, Inc. generates $0.20 in operating cash flow ($1.1M OCF vs $5.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$736K

QoQ+105.6%

Seres Therapeutics, Inc. generated $736K in revenue in Q2 2026. Against the prior quarter it is up 105.6%.

EBITDA

-$20.6M

YoY+13.5%

QoQ-2.4%

Seres Therapeutics, Inc.'s EBITDA was -$20.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.5% from the same quarter a year earlier. Against the prior quarter it is down 2.4%.

Net Income

$4.6M

YoY+123.1%

QoQ+123.0%

Seres Therapeutics, Inc. reported $4.6M in net income in Q2 2026. This represents an increase of 123.1% from the same quarter a year earlier. Against the prior quarter it is up 123.0%.

EPS (Diluted)

$0.47

YoY+120.7%

QoQ+122.6%

Seres Therapeutics, Inc. earned $0.47 per diluted share (EPS) in Q2 2026. This represents an increase of 120.7% from the same quarter a year earlier. Against the prior quarter it is up 122.6%.

Cash & Balance Sheet

Free Cash Flow

-$22.4M

YoY-66.3%

QoQ-36.9%

Seres Therapeutics, Inc. recorded an outflow of $22.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 66.3% from the same quarter a year earlier. Against the prior quarter it is down 36.9%.

Cash & Debt

$15.6M

YoY-65.6%

QoQ-47.7%

5Y CAGR-26.8%

10Y CAGR-12.6%

Seres Therapeutics, Inc. held $15.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

10M

YoY+13.6%

Seres Therapeutics, Inc. had 10M shares outstanding in Q2 2026. This represents an increase of 13.6% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

13.3%

YoY+73.5pp

QoQ+88.4pp

Seres Therapeutics, Inc.'s ROE was 13.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 73.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 88.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$9.1M

YoY-29.4%

QoQ-30.7%

Seres Therapeutics, Inc. invested $9.1M in research and development in Q2 2026. This represents a decrease of 29.4% from the same quarter a year earlier. Against the prior quarter it is down 30.7%.

Capital Expenditures

YoY-100.0%

Seres Therapeutics, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

MCRB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MCRB quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	$789K	$0	$0-100.0%	$7.1M-95.1%	$144.9M+336.3%	$33.2M-3.7%	$34.5M+22.1%	$28.3M-11.9%	$32.1M+47.5%	$21.8M	$0	N/A	N/A
R&D Expenses	N/A	$49.1M-24.1%	$64.6M-45.1%	$117.6M+7.2%	$109.7M-22.7%	$141.9M+56.7%	$90.6M+13.0%	$80.1M-16.5%	$96.0M+7.3%	$89.5M+9.1%	$82.0M+115.2%	$38.1M+255.4%	$10.7M+123.1%	$4.8M
SG&A Expenses	N/A	$39.2M-26.4%	$53.2M-31.4%	$77.5M+10.3%	$70.3M+1.4%	$69.3M+125.1%	$30.8M+24.4%	$24.7M-24.1%	$32.6M-4.2%	$34.0M+4.4%	$32.6M+94.6%	$16.8M+284.1%	$4.4M+250.0%	$1.2M
Operating Income	N/A	-$94.0M+22.5%	-$121.3M+37.8%	-$195.1M-8.4%	-$179.9M-179.0%	-$64.5M+26.8%	-$88.1M-22.6%	-$71.9M+28.3%	-$100.3M-9.7%	-$91.4M+1.6%	-$92.8M-69.2%	-$54.9M-263.7%	-$15.1M-149.2%	-$6.1M
EBITDA	N/A	-$89.8M+22.5%	-$115.8M+38.7%	-$188.9M-9.0%	-$173.3M-196.0%	-$58.5M+28.2%	-$81.6M-26.9%	-$64.3M+30.5%	-$92.4M-9.8%	-$84.1M+5.1%	-$88.6M-63.7%	-$54.1M-263.5%	-$14.9M-149.7%	-$6.0M
Interest Expense	N/A	$0	$0-100.0%	$2.5M-59.0%	$6.0M+106.9%	$2.9M-0.5%	$2.9M+482.5%	$502K	N/A	$1.6M+26.2%	$1.3M+1418.1%	$83K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	$5.7M+4088.2%	$136K+100.1%	-$113.7M+54.5%	-$250.2M-281.5%	-$65.6M+26.4%	-$89.1M-26.8%	-$70.3M+29.0%	-$98.9M-10.7%	-$89.4M+2.4%	-$91.6M-67.2%	-$54.8M-227.8%	-$16.7M-173.8%	-$6.1M
EPS (Basic)	N/A	$0.64	$0.00+100.0%	-$17.77-669.3%	-$2.31-220.8%	-$0.72+35.7%	-$1.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$2.43	$0.64	$0.00+100.0%	-$17.77	-$2.31-220.8%	-$0.72+35.7%	-$1.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M	8M+21.4%	6M	108M+17.9%	92M+14.9%	80M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$736K	$358K	N/A	$351K	$0	$0	N/A	$0-100.0%
R&D Expenses	$9.1M-29.4%	$13.2M+11.6%	N/A	$12.6M-23.4%	$12.9M-18.1%	$11.8M-39.4%	N/A	$16.5M-34.6%
SG&A Expenses	$7.1M-31.1%	$8.1M-32.1%	N/A	$9.5M-25.4%	$10.3M-21.5%	$11.9M-20.4%	N/A	$12.7M-34.6%
Operating Income	-$21.3M+14.5%	-$20.9M+23.2%	N/A	-$22.5M+22.9%	-$24.9M+13.8%	-$27.2M+20.9%	N/A	-$29.2M+34.6%
EBITDA	-$20.6M+13.5%	-$20.1M+23.1%	N/A	-$21.4M+22.8%	-$23.8M+13.2%	-$26.2M+20.4%	N/A	-$27.8M+35.3%
Interest Expense	N/A	N/A	N/A	N/A	$0	$0-100.0%	N/A	$0
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	$4.6M+123.1%	-$19.9M-160.9%	N/A	$8.2M-90.8%	-$19.9M+39.6%	$32.7M+181.4%	N/A	$88.8M+285.5%
EPS (Basic)	$0.47+120.7%	-$2.08-155.3%	-$1.77-1509.1%	$0.94-91.9%	-$2.27+47.7%	$3.76+168.5%	-$0.11+65.6%	$11.63+3243.2%
EPS (Diluted)	$0.47+120.7%	-$2.08-155.5%	-$1.76	$0.94	-$2.27	$3.75	-$0.11+65.6%	$11.63
Diluted Shares (Avg)	10M+11.5%	10M+10.0%	N/A	9M	9M	9M	N/A	8M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

MCRB Balance Sheet

MCRB quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$138.2M-1.2%	$139.8M-61.0%	$358.6M+2.8%	$348.8M-1.7%	$354.9M+3.5%	$342.9M+158.9%	$132.4M+9.9%	$120.5M-36.4%	$189.5M-30.5%	$272.6M+25.7%	$216.9M+84.8%	$117.3M	N/A
Current Assets	$49.4M+27.7%	$38.7M-78.0%	$175.4M-9.9%	$194.8M-35.9%	$303.6M+13.0%	$268.8M+168.3%	$100.2M+8.1%	$92.7M-40.2%	$155.1M-21.8%	$198.4M-4.5%	$207.6M+81.7%	$114.2M	N/A
Cash & Equivalents	$45.8M+48.6%	$30.8M-75.9%	$128.0M-21.5%	$163.0M-9.4%	$180.0M+55.1%	$116.0M+78.2%	$65.1M-24.1%	$85.8M+137.8%	$36.1M-33.8%	$54.5M-26.2%	$73.9M-35.3%	$114.2M+6803.6%	$1.7M
Short-Term Investments	$0	$0	$0-100.0%	$18.3M-83.5%	$110.7M-19.5%	$137.6M+363.3%	$29.7M	$0-100.0%	$113.9M-17.9%	$138.7M+5.8%	$131.1M	$0	$0
Inventory	N/A	N/A	$29.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$157K	$0	N/A	N/A	N/A	$9.4M+425.9%	$1.8M	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0-100.0%	$495K-99.0%	$49.8M	$0	$0	$0-100.0%	$36.8M	$0	$0	$0
Total Liabilities	$94.0M-25.4%	$126.0M-68.8%	$403.5M+19.4%	$338.0M+51.3%	$223.4M+32.8%	$168.2M-7.0%	$180.8M+7.3%	$168.5M+30.8%	$128.8M-8.0%	$140.0M+1116.9%	$11.5M-92.0%	$144.1M	N/A
Current Liabilities	$19.3M-53.1%	$41.2M-58.2%	$98.7M+15.3%	$85.6M+4.1%	$82.3M+77.2%	$46.4M+0.9%	$46.0M+9.4%	$42.0M+32.9%	$31.6M+3.8%	$30.5M+178.9%	$10.9M+114.0%	$5.1M	N/A
Non-Current Liabilities	$74.7M-12.0%	$84.8M-72.2%	$304.8M+20.8%	$252.4M+78.9%	$141.1M+15.9%	$121.8M-9.6%	$134.8M+6.6%	$126.5M+30.1%	$97.2M-11.3%	$109.6M+18595.9%	$586K-99.6%	$139.0M	N/A
Long-Term Debt	N/A	N/A	$110.0M+120.0%	$50.0M+107.9%	$24.1M-3.8%	$25.0M0.0%	$25.0M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$44.2M+220.8%	$13.8M+130.7%	-$44.9M-516.0%	$10.8M-91.8%	$131.5M-24.7%	$174.8M+461.6%	-$48.3M-0.6%	-$48.0M-179.2%	$60.7M-54.2%	$132.6M-35.4%	$205.4M+868.7%	-$26.7M-140.4%	-$11.1M
Retained Earnings	-$972.4M+0.6%	-$978.1M0.0%	-$978.2M-13.2%	-$864.5M-40.7%	-$614.4M-11.9%	-$548.8M-19.4%	-$459.6M-18.0%	-$389.4M-47.7%	-$263.6M-51.3%	-$174.2M-110.9%	-$82.6M-196.8%	-$27.8M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$101.6M-29.4%	$117.6M-28.4%	$138.2M-1.2%	$143.5M-19.7%	$143.8M-55.3%	$164.2M-51.9%	$139.8M-61.0%	$178.7M-51.4%
Current Assets	$42.3M-13.0%	$31.8M-51.8%	$49.4M+27.7%	$51.5M-29.3%	$48.7M-67.4%	$66.1M-60.0%	$38.7M-78.0%	$72.9M-66.0%
Cash & Equivalents	$15.6M-65.6%	$29.8M-49.3%	$45.8M+48.6%	$47.6M-28.7%	$45.4M-36.3%	$58.8M-47.1%	$30.8M-75.9%	$66.8M-60.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$274K	$233K	$157K	$351K	N/A	N/A	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$67.1M-39.5%	$91.1M-19.9%	$94.0M-25.4%	$99.8M-35.6%	$110.8M-72.9%	$113.7M-71.6%	$126.0M-68.8%	$154.8M-59.6%
Current Liabilities	$20.0M-35.3%	$19.3M-38.2%	$19.3M-53.1%	$22.4M-65.4%	$30.9M-71.4%	$31.3M-68.2%	$41.2M-58.2%	$64.8M-18.2%
Non-Current Liabilities	$47.0M-41.2%	$71.8M-12.9%	$74.7M-12.0%	$77.3M-14.0%	$79.9M-73.4%	$82.4M-72.8%	$84.8M-72.2%	$90.0M-70.4%
Total Equity	$34.5M+4.8%	$26.5M-47.5%	$44.2M+220.8%	$43.7M+82.7%	$33.0M+137.8%	$50.5M+184.5%	$13.8M+130.7%	$23.9M+258.2%
Retained Earnings	-$987.7M-2.3%	-$992.3M-5.0%	-$972.4M+0.6%	-$957.1M+0.6%	-$965.3M+8.2%	-$945.4M+7.2%	-$978.1M0.0%	-$962.5M-2.7%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

MCRB Cash Flow Statement

MCRB quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$51.3M	$1.1M+100.8%	-$148.6M-26.6%	-$117.4M+48.7%	-$228.8M-3521.3%	$6.7M+107.1%	-$93.6M-22.3%	-$76.5M-21.7%	-$62.9M+16.8%	-$75.5M-272.0%	$43.9M+207.5%	-$40.8M-294.3%	-$10.4M-94.7%	-$5.3M
Depreciation & Amortization	N/A	$4.1M-24.4%	$5.5M-12.4%	$6.2M-5.8%	$6.6M+11.5%	$5.9M-9.6%	$6.6M-13.5%	$7.6M-3.3%	$7.9M+8.3%	$7.3M+72.6%	$4.2M+477.6%	$728K+283.2%	$190K+115.9%	$88K
Stock-Based Compensation	N/A	$10.8M-48.3%	$21.0M-38.5%	$34.1M+33.8%	$25.5M+26.0%	$20.2M+129.2%	$8.8M+5.8%	$8.3M-49.9%	$16.6M-4.2%	$17.4M+3.0%	$16.9M+73.9%	$9.7M+368.8%	$2.1M+889.5%	$209K
Capital Expenditures	$37K	$252K-33.7%	$380K-95.2%	$8.0M-18.8%	$9.8M+2.7%	$9.6M+1518.6%	$591K-41.0%	$1.0M-48.3%	$1.9M-58.6%	$4.7M-78.2%	$21.5M+392.7%	$4.4M+335.8%	$1.0M+475.3%	$174K
Free Cash Flow	-$51.3M	$865K+100.6%	-$149.0M-18.9%	-$125.3M+47.5%	-$238.6M-8191.8%	-$2.9M+96.9%	-$94.2M-21.5%	-$77.5M-19.6%	-$64.8M+19.2%	-$80.2M-457.6%	$22.4M+149.6%	-$45.2M-298.0%	-$11.4M-106.7%	-$5.5M
Investing Cash Flow	$187K	-$42K-100.0%	$142.3M+1244.7%	$10.6M-87.2%	$82.4M+28.6%	$64.1M+140.3%	-$158.9M-420.6%	-$30.5M-127.2%	$112.3M+101.6%	$55.7M+184.9%	-$65.6M	N/A	N/A	N/A
Financing Cash Flow	$14.9M	$13.9M+115.4%	-$90.4M-226.0%	$71.7M-44.7%	$129.6M+10901.9%	$1.2M-99.6%	$303.4M+251.9%	$86.2M+32075.7%	$268K+222.9%	$83K-96.1%	$2.1M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$33K	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$22.4M-68.5%	-$16.4M-160.8%	-$14.7M+62.2%	$2.2M+106.4%	-$13.3M+66.6%	$26.9M+176.4%	-$38.9M	-$34.7M+41.5%
Depreciation & Amortization	$670K-36.7%	$781K-27.4%	$954K-12.1%	$1.0M-25.6%	$1.1M-25.4%	$1.1M-31.0%	$1.1M	$1.4M-16.6%
Stock-Based Compensation	$1.7M-25.7%	$1.8M-37.4%	N/A	$2.5M-52.1%	$2.3M-57.7%	$2.8M-56.6%	N/A	$5.2M-40.2%
Capital Expenditures	$0-100.0%	$0-100.0%	$29K-67.8%	$8K-93.8%	$181K+82.8%	$34K-45.2%	$90K	$129K-92.8%
Free Cash Flow	-$22.4M-66.3%	-$16.4M-160.9%	-$14.7M+62.2%	$2.2M+106.3%	-$13.5M+66.2%	$26.9M+176.1%	-$39.0M	-$34.8M+43.0%
Investing Cash Flow	$14K+107.7%	$0+100.0%	$181K+301.1%	-$8K-100.0%	-$181K-113.9%	-$34K+45.2%	-$90K	$141.1M+7954.4%
Financing Cash Flow	$1.7M	$428K-63.7%	$12.7M+628.7%	$61K+100.1%	$0	$1.2M-93.7%	$1.7M	-$110.9M-7783.4%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MCRB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MCRB quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	-11910.1%	N/A	N/A	-2524.1%	-44.5%	-265.3%	-208.3%	-354.8%	-284.7%	-426.5%	N/A	N/A	N/A
Net Margin	721.9%	N/A	N/A	-3509.5%	-45.3%	-268.3%	-203.7%	-350.0%	-278.4%	-420.7%	N/A	N/A	N/A
Return on Equity	12.9%+11.9pp	1.0%	N/A	-2319.9%-2270.1pp	-49.9%+1.1pp	-51.0%	N/A	N/A	-147.3%-78.2pp	-69.0%-42.4pp	-26.7%	N/A	N/A
Return on Assets	4.1%+4.0pp	0.1%+31.8pp	-31.7%+40.0pp	-71.7%-53.2pp	-18.5%+7.5pp	-26.0%+27.1pp	-53.1%+29.1pp	-82.1%-35.0pp	-47.2%-13.6pp	-33.6%-8.3pp	-25.3%-11.0pp	-14.2%	N/A
Current Ratio	2.56+1.6x	0.94-0.8x	1.78-0.5x	2.28-1.4x	3.69-2.1x	5.79+3.6x	2.180.0x	2.20-2.7x	4.90-1.6x	6.51-12.5x	19.01-3.4x	22.39	N/A
Debt-to-Equity	2.13-7.0x	9.14	N/A	4.64+4.5x	0.180.0x	0.14	N/A	N/A	2.12+1.1x	1.06+1.0x	0.06	N/A	N/A
Asset Turnover	0.010.0x	0.000.0x	0.000.0x	0.02-0.4x	0.41+0.3x	0.10-0.2x	0.260.0x	0.23+0.1x	0.17+0.1x	0.08+0.1x	0.00	N/A	N/A
FCF Margin	109.6%	N/A	N/A	-3347.9%	-2.0%	-283.6%	-224.7%	-229.2%	-249.8%	103.0%	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-2890.3%	-5839.9%	N/A	-6403.7%	N/A	N/A	N/A	N/A
Net Margin	622.4%	-5562.3%	N/A	2337.3%	N/A	N/A	N/A	N/A
Return on Equity	13.3%+73.5pp	-75.1%-139.9pp	N/A	18.8%-352.4pp	-60.3%	64.8%	N/A	371.1%
Return on Assets	4.5%+18.3pp	-16.9%-36.8pp	N/A	5.7%-44.0pp	-13.8%-3.6pp	19.9%+31.7pp	N/A	49.7%+62.7pp
Current Ratio	2.11+0.5x	1.65-0.5x	2.56+1.6x	2.30+1.2x	1.57+0.2x	2.11+0.4x	0.94-0.8x	1.12-1.6x
Debt-to-Equity	1.94-1.4x	3.44+1.2x	2.13-7.0x	2.28-4.2x	3.36	2.25	9.14	6.47
Asset Turnover	0.010.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x
FCF Margin	-3042.7%	-4569.8%	N/A	626.2%	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Seres Therapeutics, Inc. MCRB	FY2025	$789K	$5.7M	N/A	$27.2M	—
Alpha Cognition Inc. ACOG	FY2025	$10.2M	-$20.7M	N/A	$196.9M	34/100
Greenwich LifeSciences, Inc. GLSI	FY2025	N/A	-$19.4M	N/A	$242.6M	—
Instil Bio, Inc. TIL	FY2025	N/A	-$71.4M	N/A	$45.7M	—
SANGAMO THERAPEUTICS INC SGMO	FY2025	$39.6M	-$122.9M	N/A	$55.9M	—
Coherus Oncology, Inc. CHRS	FY2025	$42.2M	$168.0M	N/A	$165.3M	61/100

Where Seres Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Seres Therapeutics, Inc.'s annual revenue?

Seres Therapeutics, Inc. (MCRB) reported $789K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Seres Therapeutics, Inc. profitable?

Yes, Seres Therapeutics, Inc. (MCRB) reported a net income of $5.7M in fiscal year 2025.

What is Seres Therapeutics, Inc.'s EBITDA?

Seres Therapeutics, Inc. (MCRB) had EBITDA of -$89.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Seres Therapeutics, Inc.'s return on equity (ROE)?

Seres Therapeutics, Inc. (MCRB) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Seres Therapeutics, Inc.'s free cash flow?

Seres Therapeutics, Inc. (MCRB) generated $865K in free cash flow during fiscal year 2025. This represents a 100.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Seres Therapeutics, Inc.'s operating cash flow?

Seres Therapeutics, Inc. (MCRB) generated $1.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Seres Therapeutics, Inc.'s total assets?

Seres Therapeutics, Inc. (MCRB) had $138.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Seres Therapeutics, Inc.'s capital expenditures?

Seres Therapeutics, Inc. (MCRB) invested $252K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Seres Therapeutics, Inc. spend on research and development?

Seres Therapeutics, Inc. (MCRB) invested $49.1M in research and development during fiscal year 2025.

How many shares does Seres Therapeutics, Inc. have outstanding?

Seres Therapeutics, Inc. (MCRB) had 10M shares outstanding as of fiscal year 2025.

What is Seres Therapeutics, Inc.'s current ratio?

Seres Therapeutics, Inc. (MCRB) had a current ratio of 2.56 as of fiscal year 2025, which is generally considered healthy.

What is Seres Therapeutics, Inc.'s debt-to-equity ratio?

Seres Therapeutics, Inc. (MCRB) had a debt-to-equity ratio of 2.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Seres Therapeutics, Inc.'s return on assets (ROA)?

Seres Therapeutics, Inc. (MCRB) had a return on assets of 4.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Seres Therapeutics, Inc.'s P/E ratio?

Seres Therapeutics, Inc. (MCRB) trades at 4.8x earnings, its market capitalization divided by net income of $5.7M net income, FY2025. The market capitalization is $27.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Seres Therapeutics, Inc.'s price-to-sales ratio?

Seres Therapeutics, Inc. (MCRB) trades at 34.5x sales, its market capitalization divided by revenue of $789K revenue, FY2025. The market capitalization is $27.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Seres Therapeutics, Inc.'s Altman Z-Score?

Seres Therapeutics, Inc. (MCRB) has an Altman Z-Score of -11.65, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Seres Therapeutics, Inc.'s Piotroski F-Score?

Seres Therapeutics, Inc. (MCRB) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Seres Therapeutics, Inc.'s earnings high quality?

Seres Therapeutics, Inc. (MCRB) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.